We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATHX
201
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$823K 0.03%
114
+50
+78% +$3.02K
TLPH icon
202
Talphera
TLPH
$67.5M
$806K 0.03%
+10,446
New +$1.37M
MDGL icon
203
Madrigal Pharmaceuticals
MDGL
$12.4B
$794K 0.03%
+11,400
New +$978K
CLLS
204
Cellectis
CLLS
$286M
$785K 0.03%
+22,700
New +$824K
BIOL
205
DELISTED
Biolase, Inc.
BIOL
$760K 0.03%
+30
New +$850K
DYAX
206
PUT
DELISTED
DYAX CORPORATION
DYAX
$757K 0.03%
+452
New +$7.04K
RCPT
207
PUT
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$742K 0.03%
+45
New +$5.69K
NURO
208
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$699K 0.03%
161
+19
+13% +$83.7K
CBAY
209
DELISTED
Cymabay Therapeutics
CBAY
$692K 0.03%
100,000
-800
-0.8% -$7.68K
CASC
210
DELISTED
Cascadian Therapeutics, Inc.
CASC
$681K 0.03%
69,659
-51,091
-42% -$501K
INSM icon
211
CALL
Insmed
INSM
$22.6B
$678K 0.03%
326
+30
+10% +$529
ACGN
212
PUT
DELISTED
Aceragen Inc
ACGN
$675K 0.03%
+13
New +$7.93K
VIRX
213
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$673K 0.03%
+1,309
New +$660K
ALKS icon
214
CALL
Alkermes
ALKS
$8.47B
$622K 0.03%
102
+48
+89% +$3.28K
IMNN icon
215
Imunon
IMNN
$6.43M
$616K 0.03%
84
-82
-49% -$570K
NUVA
216
CALL
DELISTED
NuVasive, Inc.
NUVA
$616K 0.03%
+134
New +$6.22K
MDCO
217
CALL
DELISTED
Medicines Co
MDCO
$611K 0.03%
+218
New +$6.12K
CTIC
218
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$600K 0.03%
33,163
+8,663
+35% +$195K
AGIO icon
219
PUT
Agios Pharmaceuticals
AGIO
$2.14B
$585K 0.02%
62
+30
+94% +$3.36K
TLPH icon
220
CALL
Talphera
TLPH
$67.5M
$585K 0.02%
+76
New +$9.94K
KITE
221
PUT
DELISTED
Kite Pharma, Inc.
KITE
$565K 0.02%
+98
New +$6.57K
MBLY
222
CALL
DELISTED
Mobileye N.V.
MBLY
$551K 0.02%
131
-77
-37% -$3K
LITS
223
Lite Strategy Inc
LITS
$33M
$531K 0.02%
14,825
-15,175
-51% -$1.36M
IMMU
224
DELISTED
Immunomedics Inc
IMMU
$528K 0.02%
+137,751
New +$599K
GEVA
225
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$527K 0.02%
+54
New +$5.72K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.